Serum antibodies to Aspergillus fumigatus catalase in patients with cystic fibrosis. 1988

H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
Institute of Medical Microbiology, University of Aarhus, Denmark.

Seven to ten percent of patients with cystic fibrosis had serum antibodies to the catalase antigen of Aspergillus fumigatus in three cross-sectional surveys between 1977 and 1984. A total of 208 patients participated at least once, and the cumulated frequency of catalase antibodies in 94 patients included in all three surveys was 16%. The titre range was 1 to 16. The prevalence rate of Aspergillus fumigatus in sputum was 50% for a 2.5-year observation period. Catalase antibodies were strongly associated with the occurrence of Aspergillus fumigatus in sputum (p = 0.003), and the microorganism was more numerous in colonized patients with catalase antibodies than in those without such antibodies (p = 0.004). Patients with Aspergillus fumigatus in sputum and a positive catalase antibody test tended to have an adverse development as regards lung function compared to both carriers without antibodies and non-carriers. The observed differences could not, however, be related to different rates of chronic Pseudomonas aeruginosa infection.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002374 Catalase An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA. Catalase A,Catalase T,Manganese Catalase,Mn Catalase
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females

Related Publications

H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
July 1989, Archives of disease in childhood,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
March 1967, Lancet (London, England),
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
November 1970, American journal of diseases of children (1960),
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
July 2006, Clinical and molecular allergy : CMA,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
January 1995, International archives of allergy and immunology,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
March 2016, The Journal of allergy and clinical immunology,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
June 1985, European journal of clinical microbiology,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
June 1983, Sabouraudia,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
May 1994, The Journal of allergy and clinical immunology,
H Schønheyder, and T Jensen, and I H Laessøe, and N Høiby, and C Koch
August 1988, Archives of disease in childhood,
Copied contents to your clipboard!